Abstract
c-Src is a proto-oncogene involved in the genesis of and invasion by many cancers. This non-receptor tyrosine kinase also plays a crucial role in bone homeostasis, since inhibition or deletion of c-Src impairs the function of osteoclasts, the bone resorbing cells. It is thus conceivable that c-Src could be a suitable target for the pharmacological treatment of cancers, skeletal metastases and diseases of bone loss, such as osteoporosis. The pyrrolo-pyrimidines CGP77675 and CGP76030 proved to be effective in preventing bone loss in animal models, while the effect of AZD0530, a dually active inhibitor of c-Src and Bcr-ABL, on bone resorption, has been tested in a Phase I clinical trials with promising results. As far as the metastatic bone disease is concerned, c-Src inhibitors could potentially have inhibitory effects both on osteoclasts and on tumour cells, and could disrupt the vicious circle established between these cell types in the bone microenvironment. In accord with this idea, CGP76030 is able to reduce the incidence of osteolytic lesions and of visceral metastases, and to suppress morbidity and lethality in a bone metastasis mouse model without obvious adverse effects. The purine-based c-Src inhibitor AP23451 and the dual c-Src/Abl inhibitors AP22408 and AP23236 proved efficacious in reducing bone metastases in preclinical studies. These results open a new avenue for the development of innovative therapies for the treatment of bone metastatic disease.
Keywords: c-Src inhibitor, cancer, bone metastasis
Anti-Cancer Agents in Medicinal Chemistry
Title: Inhibition of Protein Kinase c-Src as a Therapeutic Approach for Cancer and Bone Metastases
Volume: 8 Issue: 3
Author(s): Nadia Rucci, Maria Susa and Anna Teti
Affiliation:
Keywords: c-Src inhibitor, cancer, bone metastasis
Abstract: c-Src is a proto-oncogene involved in the genesis of and invasion by many cancers. This non-receptor tyrosine kinase also plays a crucial role in bone homeostasis, since inhibition or deletion of c-Src impairs the function of osteoclasts, the bone resorbing cells. It is thus conceivable that c-Src could be a suitable target for the pharmacological treatment of cancers, skeletal metastases and diseases of bone loss, such as osteoporosis. The pyrrolo-pyrimidines CGP77675 and CGP76030 proved to be effective in preventing bone loss in animal models, while the effect of AZD0530, a dually active inhibitor of c-Src and Bcr-ABL, on bone resorption, has been tested in a Phase I clinical trials with promising results. As far as the metastatic bone disease is concerned, c-Src inhibitors could potentially have inhibitory effects both on osteoclasts and on tumour cells, and could disrupt the vicious circle established between these cell types in the bone microenvironment. In accord with this idea, CGP76030 is able to reduce the incidence of osteolytic lesions and of visceral metastases, and to suppress morbidity and lethality in a bone metastasis mouse model without obvious adverse effects. The purine-based c-Src inhibitor AP23451 and the dual c-Src/Abl inhibitors AP22408 and AP23236 proved efficacious in reducing bone metastases in preclinical studies. These results open a new avenue for the development of innovative therapies for the treatment of bone metastatic disease.
Export Options
About this article
Cite this article as:
Rucci Nadia, Susa Maria and Teti Anna, Inhibition of Protein Kinase c-Src as a Therapeutic Approach for Cancer and Bone Metastases, Anti-Cancer Agents in Medicinal Chemistry 2008; 8 (3) . https://dx.doi.org/10.2174/187152008783961905
DOI https://dx.doi.org/10.2174/187152008783961905 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ischemic Post-Conditioning Partially Reverses Cell Cycle Reactivity Following Ischemia/Reperfusion Injury: A Genome-Wide Survey
CNS & Neurological Disorders - Drug Targets Total Synthesis and Bioactivity of ent-homospisulosine and N,O-diacetylhomoclavaminol A
Current Organic Chemistry Driving Neural Stem Cells Towards a Desired Phenotype
Current Stem Cell Research & Therapy Autophagy in Chronic Myeloid Leukaemia: Stem Cell Survival and Implication in Therapy
Current Cancer Drug Targets Performance of Feature Selection Methods
Current Genomics MicroRNAs in Cancer Stem Cells: New Regulators of Stemness
Current Pharmaceutical Design Analysis of Four Types of Leukemia Using Gene Ontology Term and Kyoto Encyclopedia of Genes and Genomes Pathway Enrichment Scores
Combinatorial Chemistry & High Throughput Screening The Need for Diagnostic Criteria in Systemic Vasculitis
Current Immunology Reviews (Discontinued) Functional Consequences of Immune Cell Adhesion to Endothelial Cells
Current Pharmaceutical Design Anticancer Mechanisms of Bioactive Peptides
Protein & Peptide Letters The Role of Anaphylatoxins C3a and C5a in Regulating Innate and Adaptive Immune Responses
Inflammation & Allergy - Drug Targets (Discontinued) Role of the Bone Marrow Microenvironment in Drug Resistance of Hematological Malignances
Current Medicinal Chemistry Significance of Pharmacogenetics and Pharmacogenomics Research in Current Medical Practice
Current Drug Metabolism Caspase-Independent Pathways of Programmed Cell Death: The Unraveling of New Targets of Cancer Therapy?
Current Cancer Drug Targets Genistein Affects Expression of Cytochrome P450 (CYP450) Genes in Hepatocellular Carcinoma (HEPG2/C3A) Cell Line
Drug Metabolism Letters CBP-dependent Wnt/β-catenin signaling is crucial in regulation of MDR1 transcription
Current Cancer Drug Targets Understanding Unmet Needs in the Older Acute Myeloid Leukemia (AML) Patient
Current Cancer Therapy Reviews Role of Chemokines and Their Receptors in Cancer
Current Pharmaceutical Design The HOX Genes Network in Uro-Genital Cancers: Mechanisms and Potential Therapeutic Implications
Current Medicinal Chemistry Organic Synthesis of C-Prenylated Phenolic Compounds
Current Organic Chemistry